Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
NexBio, Inc. announced today the publication "DAS181 Inhibits H5N1 Influenza Lung Virus Infection of Human Lung Tissues" in the September, 2009 issue of the journal Antimicrobial Agents and Chemotherapy (AAC).
An MIT Sloan School of Management expert on U.S. vaccine markets is “cautiously hopeful” that public and private sector players are far better prepared for North America’s upcoming flu season than they have been for earlier flu pandemics.
A U.S. presidential panel report released Monday estimates H1N1 (swine) flu could infect up to half of the country's population, the Washington Post reports.
Scientists at The University of Nottingham and Health Protection Agency East Midlands are carrying out urgent research into the swine flu virus after being commissioned as part of the government's response to the pandemic.
The U.S. Food and Drug Administration today announced it has issued an Emergency Use Authorization (EUA) that allows a 2009 H1N1 influenza virus test to be used to detect the virus in troops serving overseas.
Aastra, a leading provider of IP-Telephony and Contact Center solutions, offers a solution for contact centers needing an alternative for premises-based agents if it is necessary to close the call center due to a disaster or flu epidemic. Aastra’s CC:LifeLine™ (www.aastraondemand.com/solutions-cclifeline2.asp) provides a virtual call center environment ensuring that agents can serve customers even if the physical call center is inaccessible.
PuriCore (LSE: PURI), the life sciences company focused on developing and commercializing proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment, today announces its interim results for the six months ending June 30, 2009. An H1 2009 Operating and Financial Report and detailed financial results are available here at PuriCore’s website.
Worries about the H1N1 virus haven't changed most Americans' hand washing habits, says a national survey by Bradley Corporation, a leading manufacturer of commercial bathroom and locker room furnishings.
"Business as usual” won’t be this flu season, with the effects of the H1N1 (Swine Flu) pandemic expected to include quarantines, travel restrictions and school and office closings. Businesses that rely on travel need to make preparations now to mitigate the impact.
School systems throughout the nation have a strong ally in mitigating a resurgence of swine flu this fall. UNOTRON (www.unotron.com), worldwide creator of medical grade, washable computer keyboards, scroll wheel mice, and smartcard readers, announces that it is teaming up with GHA Technologies, Inc. (www.gha-associates.com) to offer Unotron’s high quality, washable data input and security devices.
Temptime Corporation announced today that its FREEZEmarker® temperature indicator has been selected for use on H1N1 vaccines scheduled to be distributed in the US later this year.
Visitors attending the Minnesota State Fair will find some great health deals when they stop by Health Fair 11 at the Fair. More than a dozen organizations will offer free or low-cost health screenings. Among the screenings are: cholesterol testing (non-fasting), diabetes screening (glucose -- non-fasting), blood pressure checks, blood typing, hearing and vision assessments, bone density and body fat measurements, and weight readings.
The WHO's flu chief Keiji Fukuda on Saturday called upon wealthy nations and vaccine manufacturers to donate H1N1 (swine) flu vaccines to developing countries, the Associated Press reports.
CSL Biotherapies has announced the initiation of the company’s first U.S. clinical trials of its candidate Influenza A/H1N1 2009 vaccine. Study investigators will administer vaccinations to the first U.S. study volunteers today, August 24. The studies will determine the safety of CSL’s candidate vaccine and its ability to elicit an immune response (also referred to as immunogenicity) in adults and children.
The Tech-Aid Institute, http://www.techaidinstitute.com, is launching a national campaign to educate people with intellectual and other developmental disabilities about how to protect themselves from germs that include the 2009 flu pandemic that is commonly known as the Swine (H1N1) Flu.
Marin Catholic High School (MCHS) and CSG, the worldwide leader in environmentally-beneficial surface treatments, today announced the school is the Bay Area's first education facility to integrate the Surface Antimicrobial System (SAS). The most environmentally friendly and long-lasting treatment of its kind, SAS has transformed 10,000 square feet of high-touch surfaces in Marin's athletic facility into materials that continuously inhibit the growth of harmful bacteria, mold, and fungi for three years.
In the coming months, countries should prepare for an "explosion" in new cases of H1N1 (swine) flu until peak transmission of the virus is reached, WHO Western Pacific Director Shin Young-soo told a symposium of health officials gathered in Beijing Friday, the Associated Press reports.
Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Naval Health Research Center for preclinical studies evaluating Adamas' triple combination antiviral drug (TCAD) therapy for influenza A, including novel influenza A/H1N1. TCAD therapy includes Adamas' investigational proprietary fixed-dose oral combination drug, to be administered adjunctively with a neuraminidase inhibitor, including Tamiflu (oseltamivir phosphate, Roche).
Applied Nanoscience Inc. (ANI) (PINKSHEETS: APNN), a nanotechnology-based filtration development company, today announced it has reached a joint venture agreement to begin production on a disposable protective face mask with its Asia Pacific region partner. The protective mask will incorporate ANI's proprietary NanoFense™ technology, a U.S. patent pending antimicrobial nanoparticle formulation.
UnitedHealth Group (NYSE: UNH) announced today that the company will cover the administration of the H1N1 (swine flu) vaccine for its members whose health benefit plans cover immunizations, and also cover the administration of the vaccine for members whose plans currently do not include immunizations and do not plan to in the future.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.